This work identified ANCR as a new TGF-β downstream molecule in breast cancer metastasis, and hence implicated that ANCR may become a prognostic biomarker and an anti-metastasis therapy target for breast cancer. This evidence concerns the gene TGFB1 and breast carcinoma.